Retifanlimab Granted Accelerated Approval for Metastatic/Recurrent Merkel Cell Carcinoma
Keira Smith
Expert Analysis
The FDA has granted accelerated approval to retifanlimab-dlwr (Zynyz™, Incyte), a programmed cell death protein 1 (PD-1)–blocking antibody, for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). "Retifanlimab is a humanized, hinge-stabilized immunoglobulin G4 kappa (IgG4κ) anti–PD-1 monoclonal antibody with sa...
Knowledge Gains for Immunotherapeutic Strategies in Cervical Cancer
Lyn Brook
Practice Patterns
i3 Health has provided an educational activity that has challenged knowledge gaps experienced by the health care team regarding updates on immunotherapeutic strategies for recurrent or metastatic cervical cancer. This continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity, which was presented as bo...
Rare Disease Day With Thomas Abrams, MD; Maria Badillo, MSN, RN, OCN®, CCRP; and Ulka Vaishampayan, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Rare Disease Day With Thomas Abrams, MD; Maria Badillo, RN, OCN®, CCRP; and Ulka Vaishampayan, MD In honor of Rare Disease Day on February 28, the Oncology Data Advisor Editorial Board held a live panel discussion that featured updates on rare gastrointestinal cancers from Dr. Thomas Abrams, Assistant Professor of Medicine at Harvard Medical School; perspectives on nursing management of mantle cell lymphoma from Maria Badillo, Research Nurse Manager at MD Anderson Cancer Center; and updates on rare genitourinary cancers from Dr. Ulka Vaishampayan, Professor of Internal Medicine at the University of Michigan Rogel Cancer Center.  
Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials With Ticiana Leal, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials With Ticiana Leal, MD Last year, Dr. Ticiana Leal, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, recorded a continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity titled Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer (NSCLC). With numerous developments in the field occurring since recording the activity, including new FDA approvals and clinical trial results, Dr. Leal sat down with Oncology Data Advisor to provide an update on the rapidly evolving field of NSCLC immunotherapy.  
Investigating Brentuximab Vedotin for Advanced-Stage Hodgkin Lymphoma With Habte Yimer, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Investigating Brentuximab Vedotin for Advanced-Stage Hodgkin Lymphoma With Habte Yimer, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Habte Yimer of Texas Oncology sat down with Oncology Data Advisor to elaborate on the promising results of brentuximab vedotin for patients with advanced-stage classical Hodgkin lymphoma, including the most recent data and future directions for the trial.  
Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials With Ticiana Leal, MD
Keira Smith
Expert Analysis
Last year, Dr. Ticiana Leal, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, recorded a continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity titled Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer (NSCLC). With nu...
Investigating Momelotinib for Treatment of Myelofibrosis With Srdan Verstovsek, MD, PhD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Investigating Momelotinib for Treatment of Myelofibrosis With Srdan Verstovsek, MD, PhD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Srdan Verstovsek, Chief of the Section for Myeloproliferative Neoplasms in the Department of Leukemia at MD Anderson Cancer Center, sat down to discuss h...
Describing Real-World Treatment Patterns for Myelodysplastic Syndromes With Ira Zackon, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Describing Real-World Treatment Patterns for Myelodysplastic Syndromes With Ira Zackon, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Ira Zackon sat down with Oncology Data Advisor to discuss his abstract regarding real-world treatment patterns and survival outcomes among patients with myelodysplastic syndromes (MDS), including ways for making clinical trial data applicable for patients treated in the community oncology setting.  
How to Counsel Genitourinary Cancer Patients About COVID-19 Vaccine Safety With Hyma Polimera, MD
Keira Smith
Expert Analysis
At the recent American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, Dr. Hyma Polimera, a Hematology/Oncology Fellow at Penn State Cancer Institute, presented her research regarding COVID-19 vaccine behaviors and outcomes among patients with genitourinary cancers. In this follow-up interview, she explains the efficacy of COVI...
Studying Olutasidenib in Relapsed/Refractory Acute Myeloid Leukemia With Jorge Cortes, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Studying Olutasidenib in Relapsed/Refractory Acute Myeloid Leukemia With Jorge Cortes, MD At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Jorge Cortes, Director of the Georgia Cancer Center in Augusta, Georgia, sat down with Oncology Data Advisor to discuss his presentation reg...
Additional Advances in Graft-Versus-Host Disease Research and Clinical Trials With Shernan Holtan, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Additional Advances in Graft-Versus-Host Disease Research and Clinical Trials: Shernan Holtan, MD At the 2022 American Society of Hematology (ASH) Annual Meeting, Dr. Shernan Holtan, Associate Professor at the University of Minnesota Medical School, presented a late-breaking abstract on the BMT CTN 1703 trial of post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as graft-versus-host disease (GVHD) prophylaxis after allogenic hematopoietic cell transplantation. Prior to the presentation, she sat down with Oncology Data Advisor to preview the trial's promising results and its potential to transform practice for GVHD.  
Abemaciclib With Endocrine Therapy Receives Expanded Approval for Early Breast Cancer
Lyn Brook
FDA Updates
The FDA has granted approval to abemaciclib (Verzenio®, Eli Lilly and Company) with endocrine therapy—tamoxifen or an aromatase inhibitor—for treatment of adult patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative, node-positive early breast cancer that is at a high risk of recurrence. Patients cons...
Rare Disease Day With Thomas Abrams, MD; Maria Badillo, MSN, RN, OCN®, CCRP; and Ulka Vaishampayan, MD
Keira Smith
Expert Analysis
In honor of Rare Disease Day on February 28, the Oncology Data Advisor Editorial Board held a live panel discussion that featured updates on rare gastrointestinal cancers from Dr. Thomas Abrams, Assistant Professor of Medicine at Harvard Medical School; perspectives on nursing management of mantle cell lymphoma from Maria Badillo, Research Nurse Manager at MD Anderson Cancer Center; and updates on rare genitourinary cancers from Dr. Ulka Vaishampayan, Professor of Internal Medicine at the University of Michigan Rogel Cancer Center.  
Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials With Beth Sandy, MSN, CRNP
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials Just under a year ago, Beth Sandy, a Thoracic Oncology Nurse Practitioner, co-led a continuing medical education (CME)/nursing continuing professional development (NCPD)–approved activity, Harnessing Immunotherapy-Based Strateg...
Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma With Joseph Kalis, PharmD, BCOP, and Eric Cannon, PharmD, FAMCP
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma Multiple myeloma is a clonal plasma cell malignancy characterized by several cytogenetic alterations. Treatment planning for individual patients is complicated by factors such as age, frailty, comorbidities, eligibility for autolo...
Improving Gender Equity in Genitourinary Oncology Research Grants With Zain Farooq, MD
Keira Smith
Expert Analysis
At the recent American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, Dr. Zain Farooq, Hematologist/Oncologist at H. Lee Moffitt Cancer Center, presented a study investigating gender disparities in National Institutes of Health funding for genitourinary oncology research. In this follow-up interview, Dr. Farooq elaborates on the disparities experienced by women in obtaining genitourinary oncology research grants and shares the next steps for future studies addressing this issue.  
Developing Fatigue Management Guidance for Prostate Cancer Patients With Stephen Freedland, MD
Keira Smith
Expert Analysis
At the recent American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, presented his research regarding patient perspectives on fatigue management in prostate cancer. In this follow-up interview, he elaborates on the current lack of information geared toward patients experiencing fatigue while receiving novel hormonal agents and his goal of creating guidance to fill this gap.  
Reducing Risk of Prostate Cancer Progression Through Plant-Based Diets With Vivian Liu
Keira Smith
Expert Analysis
At the recent American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, Vivian Liu, Lead Clinical Research Coordinator at the University of California, San Francisco (UCSF) Osher Center for Integrative Health, presented her study investigating the association between plant-based diets and risk of disease progression in men with prostate cancer. In this follow-up interview, Ms. Liu shares additional insights into the positive health benefits of a plant-based diet for prostate cancer patients and survivors.  
Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials With Beth Sandy, MSN, CRNP
Lyn Brook
Expert Analysis
Just under a year ago, Beth Sandy, a Thoracic Oncology Nurse Practitioner, co-led a continuing medical education (CME)/nursing continuing professional development (NCPD)–approved activity, Harnessing Immunotherapy-Based Strategies For Advanced Non–Small Cell Lung Cancer (NSCLC). In this interview, she provides an update on advancements made in trea...
Optimizing Patient Outcomes With CAR T-Cell Therapy With Ola Oluwole, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Optimizing Patient Outcomes With CAR T-Cell Therapy With Ola Oluwole, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Ola Oluwole of Vanderbilt University Medical Center, sat down with Oncology Data Advisor to discuss two of his abstracts on prophylactic corticosteroid use for patients receiving axicabtagene ciloleucel and the role of cytokine release syndrome in the efficacy of chimeric antigen receptor (CAR) T-cell therapy.  

Copyright © Oncology Data Advisor. All rights reserved.